U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284485) titled 'Immunoprevention for High-risk Lung Lesions' on Dec. 08.
Brief Summary: The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
High-risk Lung Nodules
Intervention:
BIOLOGICAL: Nadunolimab
Nadunolimab will be administered 10mg/kg intravenously every 3 weeks for 4 doses
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Robert Samstein
Information provided by (Responsible Party): Robert Samstei...